Friday, February 11, 2005

I guess size does matter:

Apparently, analysts feel that Pfizer is so big that it can't grow at a rate sufficient to maintain stock values.

But given its size, the company must generate $5 billion in new revenues to achieve double digit sales growth, and some analysts doubt its pipeline products are enough for Pfizer to reach that goal. That's led some to wonder whether Pfizer is just too big and if a business model built around numerous billion-dollar products works in an era of hypersensitivity about drug costs.